Aromatase inhibitors in breast cancer therapy

Expert Review of Anticancer Therapy

Volumn 2, Issue 2, 2002, Pages 181-191

  Brueggemeier, Robert W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Aromatase; Hormone dependent breast cancer; Mechanism based inhibitors; Nonsteroidal inhibitors; Steroidal inhibitors

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; ESTROGEN SYNTHESIS; FEMALE; HUMAN; METASTASIS; POSTMENOPAUSE; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION;

EID: 0036080967     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.2.181     Document Type: Review

References (114)

1. Facts and Figures
2. Molecular basis of breast cancer
3. Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies
4. The importance of local synthesis of estrogen within the breast
5. In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione
6. The role of aromatase in breast tumors
7. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
8. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis
9. Tissue-specific promoters regulate aromatase cytochrome P450 expression
10. Purification and characterization of human placental aromatase cytochrome P450
11. Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry
12. Control of aromatase in breast cancer cells and its importance for tumor growth
13. Regulation of aromatase activity within the breast
14. Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors
15. Effects of matrix components on aromatase activity in breast stromal cells in culture
16. Aromatase 2000: Fifth International Aromatase Conference
17. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene
18. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction
19. Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin-1b and phorbol ester: Dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function
20. Nonsteroidal anti-inflammatory drugs and breast cancer
21. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer
22. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
23. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy
24. Mechanisms of action of anti-estrogens: Relevance to clinical benefits and risks
25. Tamoxifen: Toxicities and drug resistance during the treatment and prevention of breast cancer
26. Aromatase: New perspectives for breast cancer
27. Aromatase conference: Future perspectives
28. Structure-activity relationships for non-steroidal inhibitors of aromatase
29. Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer
30. Aromatase inhibitors: Specific inhibitors of oestrogen biosynthesis
31. Biochemical and molecular aspects of aromatase
32. Aromatase inhibitors-mechanisms of steroidal inhibitors
33. Mechanism and inhibition of cytochrome P450 aromatase
34. Aromatase inhibitors and breast cancer
35. Aromatase and its inhibitors
36. Use of aromatase inhibitors in breast carcinoma
37. Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta
38. Studies of human placental aromatase
39. Synthesis and biochemical evaluation of inhibitors of estrogen biosynthesis
40. Effects of the aromatase inhibitor 7 α-(4′-amino)phenylthio-4-androstene-3,17-dione in MCF-7 human mammary carcinoma cell culture
41. Aromatase inhibition by 7-substituted steroids in human choriocarcinoma cell culture
42. Effects of the aromatase inhibitor 7 α-(4′-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats
43. Inhibition of aromatase cytochrome P450 by 10-oxirane and 10-thiirane substituted androgens. Implications for the structure of the active site
44. Stereoselective inhibition of human placental aromatase
45. Stereoselective inhibition of aromatase by novel epoxysteroids
46. Thiol-containing androgens as suicide substrates of aromatase
47. Steroidal C-19 sulfur and nitrogen derivatives designed as aromatase inhibitors
48. Time-dependent inhibition of human placental aromatase with a 2,19-methyleneoxy-bridged androstenedione
49. A-ring bridged steroids as potent inhibitors of aromatase
50. Biological characterization of A-ring steroids
51. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo
52. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer
53. Effects of aromatase inhibitors, aminoglutethimide and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors
54. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model
55. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer
56. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report
57. Aromatase inhibition: Basic concepts and the pharmacodynamics of formestane
58. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat
59. Formestane, a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer
60. Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity
61. Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-ace
62. Potent enzyme-activated inhibition of aromatase by a 7 a-substituted C19 steroid
63. 7-substituted 1,4,6-androstatriene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase
64. Synthesis and biochemical studies of 7 a-substituted androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase
65. 7a-Arylaliphatic androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase
66. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor
67. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): Antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors
68. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats
69. Novel irreversible aromatase inhibitors
70. First generation aromatase inhibitors-aminoglutethimide and testololactone
71. Experience with aromatase inhibitors in the treatment of advanced breast cancer
72. Effect of ketoconazole on human ovarian C17,20-desmolase and aromatase
73. Novel aromatase inhibitors
74. Aromatase inhibitors: Synthesis, biological activity and binding mode of azole-type compounds
75. R76713 and enantiomers: Selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis
76. Vorozole, a specific non-steroidal aromatase inhibitor
77. Arimidex: A potent and selective fourth-generation aromatase inhibitor
78. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
79. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
80. Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer
81. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer
82. Endocrine treatment of breast cancer in women
83. Aromatase inhibitors in the treatment of breast cancer
84. Aromatase inhibitors in the treatment and prevention of breast cancer
85. Aromatase inhibition and anti-estrogen therapy in early breast cancer treatment and chemoprevention
86. Endocrine therapy in the treatment of metastatic breast cancer
87. Role of anti-aromatase agents in postmenopausal advanced breast cancer
88. Nonsteroidal and steroidal aromatase inhibitors in breast cancer
89. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer
90. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer
91. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
92. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
93. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials
94. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
95. Anastrozole is superior to tamoxifen as firstline therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
96. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
97. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
98. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
99. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
100. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a Phase III study of the International Letrozole Breast Cancer Group
101. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women
102. The minimal effective exemestane dose for endocrine activity in advanced breast cancer
103. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
104. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A Phase II trial
105. Pharmacology and clinical experience with exemestane
106. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women
107. Letrozole (Femara) is a more effective antiproliferative agent than tamoxifen irrespective of ErbB1 and/or ErbB2 positive status: Evidence from a Phase III randomized trial of neoadjuvant endocrine therapy for with estrogen receptor positive primary breast cancer
108. Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: Toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone
109. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors
110. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats
111. Antitumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors